glp 1 for cardiovascular disease Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care Real-World Evidence for GLP-1 Receptor
Description
doi: 10.1007/s00125-009-1344-5
Testing reveals whether your biology predicts rapid rebound (suggesting continuous therapy is medically justified) or slower weight regain (allowing safer discontinuation if desired)
Drug safety data mining with a tree-based scan statistic
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
The launch of oral GLP-1s coupled with lower prices and broader access (including Medicare and Medicaid coverage in the U.S.) should drive higher utilization and market penetration as more affordable and convenient options become available, Schott said
